Facciolà G - Search Results

1

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.

Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML. Scordo MG, et al. Among authors: facciola g. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171. Psychopharmacology (Berl). 1999. PMID: 10639689 Clinical Trial.

2

Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline.

Spina E, Avenoso A, Salemi M, Facciolá G, Scordo MG, Ancione M, Madia A. Spina E, et al. Among authors: facciola g. Pharmacopsychiatry. 2000 Nov;33(6):213-7. doi: 10.1055/s-2000-8361. Pharmacopsychiatry. 2000. PMID: 11147928 Clinical Trial.

3

Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate.

Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Giacobello T, Madia AG, Perucca E. Spina E, et al. Among authors: facciola g. Ther Drug Monit. 2000 Aug;22(4):481-5. doi: 10.1097/00007691-200008000-00019. Ther Drug Monit. 2000. PMID: 10942191

4

No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers.

Avenoso A, Facciolà G, Scordo MG, Spina E. Avenoso A, et al. Among authors: facciola g. Ther Drug Monit. 1999 Oct;21(5):577-9. doi: 10.1097/00007691-199910000-00015. Ther Drug Monit. 1999. PMID: 10519458 Clinical Trial.

5

Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders.

Facciolà G, Avenoso A, Scordo MG, Madia AG, Ventimiglia A, Perucca E, Spina E. Facciolà G, et al. Ther Drug Monit. 1999 Jun;21(3):341-5. doi: 10.1097/00007691-199906000-00017. Ther Drug Monit. 1999. PMID: 10365650 Clinical Trial.

6

Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.

Spina E, Avenoso A, Facciolà G, Fabrazzo M, Monteleone P, Maj M, Perucca E, Caputi AP. Spina E, et al. Among authors: facciola g. Int Clin Psychopharmacol. 1998 May;13(3):141-5. doi: 10.1097/00004850-199805000-00009. Int Clin Psychopharmacol. 1998. PMID: 9690983

7

Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.

Avenoso A, Spinà E, Campo G, Facciolă G, Ferlito M, Zuccaro P, Perucca E, Caputi AP. Avenoso A, et al. Among authors: facciola g. Pharmacol Res. 1997 Apr;35(4):335-9. Pharmacol Res. 1997. PMID: 9264051 Clinical Trial.

8

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.

Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia A. Spina E, et al. Among authors: facciola g. Ther Drug Monit. 2001 Jun;23(3):223-7. doi: 10.1097/00007691-200106000-00007. Ther Drug Monit. 2001. PMID: 11360029

9

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.

Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E. Spina E, et al. Among authors: facciola g. Psychopharmacology (Berl). 2001 Jan 1;153(2):238-43. doi: 10.1007/s002130000576. Psychopharmacology (Berl). 2001. PMID: 11205425 Clinical Trial.

10

Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection.

Avenoso A, Facciolà G, Salemi M, Spina E. Avenoso A, et al. Among authors: facciola g. J Chromatogr B Biomed Sci Appl. 2000 Sep 15;746(2):173-81. doi: 10.1016/s0378-4347(00)00323-6. J Chromatogr B Biomed Sci Appl. 2000. PMID: 11076069

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results